Medtech firm Manus Neurodynamica seals £750,000 funding for pen that detects Parkinson’s

Edinburgh medtech firm Manus Neurodynamica has closed a £750,000 funding round to develop its digital pen which provides an early warning of Parkinson’s disease.

Par Equity led the investment which Manus will use to grow its team, develop the product, support its move into clinical trials markets and develop the next generation of products.

Par was joined in the round by Scottish Investment Bank, the investment arm of Scottish Enterprise, and Old College Capital, the University of Edinburgh’s venture fund.

Read more HERE.